|
1
|
Montesano R, Becker R, Hall J, Likhachev
A, Lu SH, Umbenhauer D and Wild CP: Repair of DNA alkylation
adducts in mammalian cells. Biochimie. 67:919–928. 1985.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pegg AE, Dolan ME and Moschel RC:
Structure, function, and inhibition of O6-alkylguanine-DNA
alkyltransferase. Prog Nucleic Acid Res Mol Biol. 51:167–223.
1995.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jacinto FV and Esteller M: MGMT
hypermethylation: A prognostic foe, a predictive friend. DNA Repair
(Amst). 6:1155–1160. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Esteller M, Hamilton SR, Burger PC, Baylin
SB and Herman JG: Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter hypermethylation
is a common event in primary human neoplasia. Cancer Res.
59:793–797. 1999.PubMed/NCBI
|
|
5
|
Qian XC and Brent TP: Methylation hot
spots in the 5'flanking region denote silencing of the
O6-methylguanine-DNA methyltransferase gene. Cancer Res.
57:3672–3677. 1997.PubMed/NCBI
|
|
6
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Bernd K, Fritz G, Mitra S and Coquerelle
T: Transfection and expression of human O6-methylguanine-DNA
methyltransferase (MGMT) cDNA in Chinese hamster cells: The role of
MGMT in protection against the genotoxic effects of alkylating
agents. Carcinogenesis. 12:1857–1867. 1991.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Glassner BJ, Weeda G, Allan JM, Broekhof
JLM, Carls NHE, Donker I, Engelward BP, Hampson RJ, Hersmus R,
Hickman MJ, et al: DNA repair methyltransferase (Mgmt) knockout
mice are sensitive to the lethal effects of chemotherapeutic
alkylating agents. Mutagenesis. 14:339–347. 1999.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hansen RJ, Nagasubramanian R, Delaney SM,
Samson LD and Dolan ME: Role of O6-methylguanine-DNA
methyltransferase in protecting from alkylating agent-induced
toxicity and mutations in mice. Carcinogenesis. 28:1111–1116.
2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang S, Song C, Zha Y and Li L: The
prognostic value of MGMT promoter status by pyrosequencing assay
for glioblastoma patients' survival: A meta-analysis. World J Surg
Oncol. 14(261)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hegi ME, Liu L, Herman JG, Stupp R, Wick
W, Weller M, Mehta MP and Gilbert MR: Correlation of
O6-Methylguanine Methyltransferase (MGMT) promoter methylation with
clinical outcomes in glioblastoma and clinical strategies to
modulate MGMT activity. J Clin Oncol. 26:4189–4199. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 343:1350–1354.
2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kulke MH, Hornick JL, Frauenhoffer C,
Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart
K, Fuchs CS and Redston MS: O6-methylguanine DNA methyltransferase
deficiency and response to Temozolomide-based therapy in patients
with neuroendocrine tumors. Clin Cancer Res. 15:338–345.
2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Walter T, Van Brakel B, Vercherat C,
Hervieu V, Forestier J, Chayvialle JA, Molin Y, Lombard-Bohas C,
Joly MO and Scoazec JY: O6-Methylguanine-DNA methyltransferase
status in neuroendocrine tumours: Prognostic relevance and
association with response to alkylating agents. Br J Cancer.
112:523–531. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kunz PL, Graham NT, Catalano PJ, Nimeiri
HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH,
et al: Randomized study of temozolomide or temozolomide and
capecitabine in patients with advanced pancreatic neuroendocrine
tumors (ECOG-ACRIN E2211). J Clin Oncol. 41:1359–1369.
2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Svrcek M, Buhard O, Colas C, Coulet F,
Dumont S, Massaoudi I, Lamri A, Hamelin R, Cosnes J, Oliveira C, et
al: Methylation tolerance due to an O6-methylguanine DNA
methyltransferase (MGMT) field defect in the colonic mucosa: An
initiating step in the development of mismatch repair-deficient
colorectal cancers. Gut. 59:1516–1526. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Millis SZ, Bryant D, Basu G, Bender R,
Vranic S, Gatalica Z and Vogelzang NJ: Molecular profiling of
infiltrating urothelial carcinoma of bladder and nonbladder origin.
Clin Genitourin Cancer. 13:e37–e49. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hadoux J, Favier J, Scoazec JY, Leboulleux
S, Ghuzlan AAl, Caramella C, Déandreis D, Borget I, Loriot C,
Chougnet C, et al: SDHB mutations are associated with response to
temozolomide in patients with metastatic pheochromocytoma or
paraganglioma. Int J Cancer. 135:2711–2720. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mithani SK, Mydlarz WK, Grumbine FL, Smith
IM and Califano JA: Molecular genetics of premalignant oral
lesions. Oral Dis. 13:126–133. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. PLoS Med. 18(e1003583)2021.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Balduzzi S, Rücker G and Schwarzer G: How
to perform a Meta-analysis with R: A practical tutorial. Evid Based
Ment Health. 22:153–160. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Viechtbauer W: Conducting Meta-analyses in
R with the metafor package. J Stat Softw. 36:1–48. 2010.
|
|
24
|
Higgins JPT, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gupta MK, Kushwah AS, Singh R, Srivastava
K and Banerjee M: Genetic and epigenetic alterations in MGMT gene
and correlation with concomitant chemoradiotherapy (CRT) in
cervical cancer. J Cancer Res Clin Oncol. 149:15159–15170.
2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cannella L, Della Monica R, Marretta AL,
Iervolino D, Vincenzi B, De Chiara AR, Clemente O, Buonaiuto M,
Barretta ML, Di Mauro A, et al: The impact of O6-Methylguanine-DNA
methyltransferase (MGMT) promoter methylation on the outcomes of
patients with leiomyosarcoma treated with dacarbazine. Cells.
12(1635)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Safar AM, Spencer H III, Su X, Coffey M,
Cooney CA, Ratnasinghe LD, Hutchins LF and Fan CY: Methylation
profiling of archived non-small cell lung cancer: A promising
prognostic system. Clin Cancer Res. 11:4400–4405. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nilsson TK, Löf-Öhlin ZM and Sun XF: DNA
methylation of the p14ARF, RASSF1A and APC1A genes as an
independent prognostic factor in colorectal cancer patients. Int J
Oncol. 42:127–133. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Brabender J, Usadel H, Metzger R,
Schneider PM, Park J, Salonga D, Tsao-Wei DD, Groshen S, Lord RV,
Takebe N, et al: Quantitative O(6)-methylguanine DNA
methyltransferase methylation analysis in curatively resected
non-small cell lung cancer: Associations with clinical outcome.
Clin Cancer Res. 9:223–227. 2003.PubMed/NCBI
|
|
30
|
Dikshit RP, Gillio-Tos A, Brennan P, De
Marco L, Fiano V, Martinez-Peñuela JM, Boffetta P and Merletti F:
Hypermethylation, risk factors, clinical characteristics, and
survival in 235 patients with laryngeal and hypopharyngeal cancers.
Cancer. 110:1745–1751. 2007.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Šupić G, Kozomara R, Branković-Magić M,
Jović N and Magić Z: Gene hypermethylation in tumor tissue of
advanced oral squamous cell carcinoma patients. Oral Oncol.
45:1051–1057. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zuo C, Ai L, Ratliff P, Suen JY, Hanna E,
Brent TP and Fan CY: O6-Methylguanine-DNA methyltransferase gene:
Epigenetic silencing and prognostic value in head and neck squamous
cell carcinoma. Cancer Epidemiol Biomarkers Prev. 13:967–975.
2009.PubMed/NCBI
|
|
33
|
Fu T, Sharmab A, Xie F, Liu Y, Li K, Wan
W, Baylin SB, Wolfgang CL and Ahuja N: Methylation of MGMT is
associated with poor prognosis in patients with stage III duodenal
adenocarcinoma. PLoS One. 11(e0162929)2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen SP, Chiu SC, Wu CC, Lin SZ, Kang JC,
Chen YL, Lin PC, Pang CY and Harn HJ: The association of
methylation in the promoter of APC and MGMT and the prognosis of
Taiwanese CRC patients. Genet Test Mol Biomarkers. 13:67–71.
2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lu C, Xie H, Wang F, Shen H and Wang J:
Diet folate, DNA methylation and genetic polymorphisms of MTHFR
C677T in association with the prognosis of esophageal squamous cell
carcinoma. BMC Cancer. 11(91)2025.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sun W, Zaboli D, Wang H, Liu Y,
Arnaoutakis D, Khan T, Khan Z, Koch WM and Califano JA: Detection
of TIMP3 promoter hypermethylation in salivary rinse as an
independent predictor of local recurrence-free survival in head and
neck cancer. Clin Cancer Res. 18:1082–1091. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Jamai D, Gargouri R, Selmi B and Khabir A:
ERCC1 and MGMT methylation as a predictive marker of relapse and
FOLFOX response in colorectal cancer patients from south tunisia.
Genes (Basel). 14(1467)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li X, Hu F, Wang Y, Yao X, Zhang Z, Wang
F, Sun G, Cui BB, Dong X and Zhao Y: CpG island methylator
phenotype and prognosis of colorectal cancer in Northeast China.
Biomed Res Int. 2014(236361)2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shima K, Morikawa T, Baba Y, Nosho K,
Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS and Ogino
S: MGMT promoter methylation, loss of expression and prognosis in
855 colorectal cancers. Cancer Causes Control. 22:301–309.
2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Niger M, Nichetti F, Casadei-Gardini A,
Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB,
Vingiani A, et al: MGMT inactivation as a new biomarker in patients
with advanced biliary tract cancers. Mol Oncol. 16:2733–2746.
2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Guadagni S, Fiorentini G, Clementi M,
Palumbo G, Masedu F, Deraco M, De Manzoni G, Chiominto A, Valenti M
and Pellegrini C: MGMT methylation correlates with melphalan pelvic
perfusion survival in stage III melanoma patients: A pilot study.
Melanoma Res. 27:439–447. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Viúdez A, Carvalho FLF, Maleki Z, Zahurak
M, Laheru D, Stark A, Azad NS, Wolfgang CL, Baylin S, Herman JG, et
al: A new immunohistochemistry prognostic score (IPS) for
recurrence and survival in resected pancreatic neuroendocrine
tumors (PanNET). Oncotarget. 7:24950–24961. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Supic G, Kozomara R, Jovic N, Zeljic K and
Magic Z: Prognostic significance of tumor-related genes
hypermethylation detected in cancer-free surgical margins of oral
squamous cell carcinomas. Oral Oncol. 47:702–708. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Taioli E, Ragin C, Wang X hong, Chen J,
Langevin SM, Brown AR, Gollin SM, Garte S and Sobol RW: Recurrence
in oral and pharyngeal cancer is associated with quantitative MGMT
promoter methylation. BMC Cancer. 9(354)2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Morano F, Corallo S, Niger M, Barault L,
Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A,
et al: Temozolomide and irinotecan (TEMIRI regimen) as salvage
treatment of irinotecan-sensitive advanced colorectal cancer
patients bearing MGMT methylation. Ann Oncol. 29:1800–1806.
2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ogino S, Kawasaki T, Kirkner GJ, Suemoto
Y, Meyerhardt JA and Fuchs CS: Molecular correlates with MGMT
promoter methylation and silencing support CpG island methylator
phenotype-Low (CIMP-Low) in colorectal cancer. Gut. 56:1564–1571.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Li Y, Lyu Z, Zhao L, Cheng H, Zhu D, Gao
Y, Shang X and Shi H: Prognostic value of MGMT methylation in
colorectal cancer: A meta-analysis and literature review. Tumour
Biol. 36:1595–1601. 2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Cai F, Xiao X, Niu X, Shi H and Zhong Y:
Aberrant Methylation of MGMT Promoter in HNSCC: A Meta-Analysis.
PLoS One. 11(e0163534)2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Choi B, Na Y, Whang MY, Ho JY, Han MR,
Park SW, Song H, Hur SY and Choi YJ: MGMT Methylation is associated
with human papillomavirus infection in cervical dysplasia: A
longitudinal study. J Clin Med. 12(6188)2023.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Chen L, Wang Y, Liu F, Xu L, Peng F, Zhao
N, Fu B, Zhu Z, Shi Y, Liu J, et al: A systematic review and
meta-analysis: Association between MGMT hypermethylation and the
clinicopathological characteristics of non-small-cell lung
carcinoma. Sci Reports. 8(1439)2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Das M, Sharma SK, Sekhon GS, Saikia BJ,
Mahanta J and Phukan RK: Promoter methylation of MGMT gene in serum
of patients with esophageal squamous cell carcinoma in North East
India. Asian Pac J Cancer Prev. 15:9955–9960. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhang L, Lu W, Miao X, Xing D, Tan W and
Lin D: Inactivation of DNA repair gene O6-methylguanine-DNA
methyltransferase by promoter hypermethylation and its relation to
p53 mutations in esophageal squamous cell carcinoma.
Carcinogenesis. 24:1039–1044. 2003.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Brighi N, Lamberti G, Andrini E, Mosconi
C, Manuzzi L, Donati G, Lisotti A and Campana D: Prospective
evaluation of MGMT-Promoter methylation status and correlations
with outcomes to Temozolomide-based chemotherapy in
Well-differentiated neuroendocrine tumors. Curr Oncol.
30:1381–1394. 2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Yagi K, Ono H, Kudo A, Kinowaki Y, Asano
D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Tanaka S and Tanabe
M: MGMT is frequently inactivated in pancreatic NET-G2 and is
associated with the therapeutic activity of STZ-based regimens. Sci
Reports. 13(7535)2023.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Niger M, Morano F, Manglaviti S, Nichetti
F, Tamborini E, Perrone F, Marcuzzo M, Peverelli G, Brambilla M,
Pagani F, et al: 732P-Is MGMT methylation a new therapeutic target
for biliary tract cancer? Ann Oncol. 30(v281)2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Bujko M, Kowalewska M, Danska-Bidzinska A,
Bakula-Zalewska E, Siedecki JA and Bidzinski M: The promoter
methylation and expression of the O6-methylguanine-DNA
methyltransferase gene in uterine sarcoma and carcinosarcoma. Oncol
Lett. 4:551–555. 2012.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Jakob J, Hille M, Sauer C, Ströbel P, Wenz
F and Hohenberger P: O6-methylguanine-DNA methyltransferase (MGMT)
Promoter methylation is a rare event in soft tissue sarcoma. Radiat
Oncol. 7(180)2012.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Schraml P, Von Teichman A, Mihic-Probst D,
Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi
M, Moch H and von Moos R: Predictive value of the MGMT promoter
methylation status in metastatic melanoma patients receiving
First-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Oncol Rep. 28:654–668. 2012.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Kazanets A, Shorstova T, Hilmi K, Marques
M and Witcher M: Epigenetic silencing of tumor suppressor genes:
Paradigms, puzzles, and potential. Biochim Biophys Acta.
1865:275–288. 2025.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Esteller M: CpG island hypermethylation
and tumor suppressor genes: A booming present, a brighter future.
Oncogene. 21:5427–5440. 2002.PubMed/NCBI View Article : Google Scholar
|
